worthind did remind us of the phase-II stats:<quote>>80% 70%

worthind did remind us of the phase-II stats:

<quote>
>80% <400 c/ml and >70% <50 c/ml
viral load drop about -1.75 or 98.3%
86% or 212 c/ml increase in cd4
no new resistance
no atc serious adverse event
23/24 enter extension
</quote>

Thanks for reminding us of the Phase-II stats for comparison, w. I'll be matching them up with Phase-III with baited breath and palpitations!

and furthermore

what will we see for atc this time? will atc phiii match the outstanding phii numbers?

Yes.


and what will the sp do on phiii results alone?

Go nuts. This is the year of the nut.


after results, partnering will be announced 5 wks later on 9 March...

An educated guess, I presume? In any case, a commercialisation deal post a good Phase-III result would send Avexa shares totally nuts.


oh, and farewell to those placement fools taking a tiny profit from 14c ...

I really can't blame anyone for taking a quick profit. I've been trying this day-trade thing myself for the last few weeks - making a profit isn't easy!

Regards,
P.

(sentiment adjusted from "LT Buy" to "ST Buy". I maintain my Long-Term sentiment, but I'm planning on playing both sides of the street. Things have been very quiet on the AVX front, but I suspect we're going to have visitors. Sometimes a rampaging crowd of day-traders can be a good thing).